Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Face mask containing Centella sinensis.
- Who it may be relevant to
- Registry conditions: Rosacea, Acne, Centella, Melasma. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.
Interventions
- Other Face mask containing Centella sinensis
A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica
Primary outcome measures
- Clinical erythema Score (CEA) [Time frame: Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.]
- Global Aesthetic Improvement Scale Score (GAIS) [Time frame: Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.]
- Melasma Area and Severity Rating (MASI) [Time frame: Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.]
Secondary outcome measures (1)
- Dermatology Quality of Life Score (DLQI) [Time frame: Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.]
Eligibility criteria
Inclusion criteria
- Meet mild to moderate rosacea, acne diagnostic criteria; Meet the diagnostic criteria for melasma;
- Over 18 years of age;
- Be able to follow the treatment rules of the study and be followed for 8 weeks;
- Informed consent; 5There were no significant cardiac, liver, kidney, gastrointestinal, neurological, psychiatric, or metabolic disorders
6.No medication was used within 1 month
Exclusion criteria
- Currently pregnant, planning to become pregnant or breastfeeding;
- Documented hypersensitivity to any active ingredient or excipient included in the study drug, or a history of adverse reactions to cosmetic products;
- Participate in other clinical studies within 3 months before the start of the study;
- Frequent use of Chinese medicine, sleeping pills, sedatives, anti-anxiety drugs or potentially addictive substances;
- Present with concomitant skin conditions that may confuse the clinical assessment of rosacea, melasma, seborrheic dermatitis or pose a risk to participants, or have a history of severe skin conditions;
- Normal use of relevant treatment (including intense pulsed light, pulsed fuel laser, oral and topical tranexamic acid, oral tetracycline antibiotics, oral compound glycyrrhizin and other anti-inflammatory drugs)
- Patients with incomplete observation data, incomplete course of treatment and inability to take drugs as prescribed by doctors were removed
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Nanjing First Hospital — Nanjing
Identifiers
NCT: NCT06763367 · KY20241217-04